Chemoimmunomodulation of MDSCS as a novel strategy for cancer therapy

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 121-122

  Djeu, Julie ^a   Wei, Sheng ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Chemoimmunotherapy; Docetaxel; Icariin; Myeloid derived suppressor cells; Tumor microenvironment; Tumor associated macrophages

Indexed keywords

3,5,7 TRIHYDROXY 4' METHOXY 8 (3 HYDROXY 3 METHYLBUTYL)FLAVONE; CHEMOKINE RECEPTOR CCR7; DOCETAXEL; FLAVONE; GAMMA INTERFERON; ICARIIN; INTERLEUKIN 10; INTERLEUKIN 12; STAT3 PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MOLECULAR DYNAMICS; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; SUPPRESSOR CELL; TARGET CELL DESTRUCTION; UPREGULATION;

EID: 84885800513     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.18074     Document Type: Note

References (10)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; http://dx.doi.org/10.1038/nri2506.
2. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22:231-7; http://dx.doi.org/10.1016/j.coi.2010.01.009.
3. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70:5728-39; http://dx.doi.org/10.1158/0008-5472.CAN-09-4672.
4. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer 2010; 103:629-41; http://dx.doi.org/10.1038/sj.bjc.6605814.
5. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16:4583-94; http://dx.doi.org/10.1158/1078-0432.CCR-10-0733.
6. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69:2514-22; http://dx.doi.org/10.1158/0008-5472.CAN-08-4709.
7. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-702; http://dx.doi.org/10.1084/jem.20061104.
8. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883.
9. Zhou J, Wu J, Chen X, Fortenbery N, Eksioglu E, Kodumudi KN, et al. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol 2011; 11:890-8; http://dx.doi.org/10.1016/j.intimp.2011.01.007.
10. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49; http://dx.doi.org/10.1084/jem.20080132.